登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C15H13N3O4S
化学文摘社编号:
分子量:
331.35
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
产品名称
吡罗昔康, United States Pharmacopeia (USP) Reference Standard
InChI
1S/C15H13N3O4S/c1-18-13(15(20)17-12-8-4-5-9-16-12)14(19)10-6-2-3-7-11(10)23(18,21)22/h2-9,19H,1H3,(H,16,17,20)
SMILES string
CN1C(C(=O)Nc2ccccn2)=C(O)c3ccccc3S1(=O)=O
InChI key
QYSPLQLAKJAUJT-UHFFFAOYSA-N
grade
pharmaceutical primary standard
API family
piroxicam
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
Gene Information
human ... PTGS1(5742), PTGS2(5743)
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
环加氧酶抑制剂。
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Application
Piroxicam USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Piroxicam Capsules
- Piroxicam Compounded Cream
- Piroxicam Compounded Oral Suspension
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Other Notes
Sales restrictions may apply.
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral - STOT RE 2 Oral
target_organs
Gastrointestinal tract
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
P Pfitzenmeyer et al.
The Journal of rheumatology, 21(8), 1573-1577 (1994-08-01)
We describe 2 patients who developed pulmonary infiltrates while being treated with piroxicam. There was no satisfactory explanation other than drug induced lung disease for their illness. They had no exposure to pneumotoxic drugs or aerocontaminants. Microorganisms were not cultured
C R Lee et al.
Drugs, 48(6), 907-929 (1994-12-01)
Piroxicam-beta-cyclodextrin is a complex of the established nonsteroidal antiinflammatory drug (NSAID) piroxicam and an inert cyclic macromolecule, beta-cyclodextrin. In clinical trials in patients with rheumatic diseases or pain arising from other conditions, it was as effective an analgesic as standard
D Gerber
Drug intelligence & clinical pharmacy, 21(9), 707-710 (1987-09-01)
During the approximately five years (1981-86) that piroxicam has been available in South Africa, the Medicines Safety Centre has received 31 reports of adverse reactions associated with this drug. Among these are two reactions not previously recorded in the literature
R E Lister et al.
European journal of rheumatology and inflammation, 12(4), 6-11 (1993-01-01)
Piroxicam-beta-cyclodextrin is a novel NSAID; it is a supermolecular inclusion complex designed to improve the risk:benefit ratio of piroxicam. In animal studies it has been shown to be as effective as piroxicam as an anti-inflammatory and analgesic agent but with
Kristine Holgersen et al.
Inflammatory bowel diseases, 21(2), 257-266 (2015-01-09)
Osteoporosis and fractures are common complications of inflammatory bowel disease. The pathogenesis is multifactorial and has been partly attributed to intestinal inflammation. The aim of this study was to evaluate bone status and assess the association between bone loss and
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持